FDA extends PDUFA goal date for BioCryst's ORLADEYO pediatric NDA to Dec 12, 2025

BIOCRYST PHARMACEUTICALS INC

FDA determined submission of additional final reports and formulation data is a major amendment, extending review by three months.
New PDUFA target action date set for December 12, 2025, after original goal date extended.
NDA seeks approval of once-daily ORLADEYO oral granules for HAE in pediatric patients aged 2 to 11 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.